Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.

ABSTRACT:

Background

High prices of anticancer medicines have increased the economic burden for both patients and health insurance systems. Since 2017, China has implemented national price negotiations for medicines, relying on evidence from health technology assessments. We aim to assess the relation between negotiated price and value of anticancer medicines listed in China's National Reimbursement Drug List (NRDL).

Methods

For all price-negotiated anticancer medicines and corresponding indications listed in the latest NRDL between 2017 and 2020, we collected their clinical outcomes data, including overall survival (OS) and progression-free survival (PFS), in supporting trials. Pearson correlation coefficient was calculated to estimate the association between the daily cost and clini

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC9270265 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature